Board & policies

Doug is a member of the Management Engagement and Remuneration Committee and a member of the Audit and Nominations Committees.

Doug McCutcheon joined the Board in 2012. He is the President of Longview Asset Management Ltd. and Gormley Limited, independent investment firms. Until 2012, Doug was an investment banker at S.G. Warburg and then UBS for 25 years, most recently as the head of Healthcare Investment Banking for Europe, the Middle East, Africa and Asia-Pacific. Doug is involved in several philanthropic organisations with a focus on healthcare and education. He attended Queen’s University, Canada.

Sven H. Borho, CFA, joined the Board in 2018. He is a founder and Managing Partner of OrbiMed. Sven heads the public equity team and he is the portfolio manager for OrbiMed’s public equity and hedge funds. He has been a portfolio manager for the firm’s funds since 1993 and has played an integral role in the growth of OrbiMed’s asset management activities. He started his career in 1991 when he joined OrbiMed’s predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. Sven studied business administration at Bayreuth University in Germany and received a M.Sc. (Econs.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.

A member of the Audit & Risk, Nominations and Management Engagement and Remuneration Committees.

Humphrey van der Klugt joined the Board in 2016. He is also a Director of Allianz Technology Trust PLC. He was formerly Chairman of Fidelity European Values PLC and a Director of Murray Income Trust PLC, BlackRock Commodities Income Investment Trust plc and of JPM Claverhouse Investment Trust plc. Prior to this Humphrey was a fund manager and Director of Schroder Investment Management Limited and in a 22 year career was a member of their Group Investment and Asset Allocation Committees. Prior to joining Schroders, he was with Peat Marwick Mitchell & Co (now KPMG) where he qualified as a Chartered Accountant in 1979.

Chair of the Nominations Committee and a member of the Audit & Risk, and Management Engagement & Remuneration Committees. Dr Rawal is also the Senior Independent Director.

Dr Rawal, a physician with 25 years’ experience in life sciences research and development, has held senior executive roles in drug development and scientific evaluation in four global pharmaceutical companies. She has also worked in senior roles with two medical research funding organisations: Wellcome Trust and Cancer Research UK.

She is currently a non-executive Director of the Central London Community Healthcare NHS Trust and is a Trustee of the Social Mobility Foundation.

Chair of the Audit & Risk Committee and a member of the Nominations and Management Engagement & Remuneration Committees.

Tim Joined the Board on 1 September 2022. A qualified accountant, Tim is the Chief Financial Officer at Caledonia Investments PLC. He is also a non-executive Director of Premier Marinas Group and a member of the Valuation and Audit & Risk Committees at Oxford University Endowment Management. He was formerly Chief Financial Officer at Wellcome Trust, the global charitable foundation focused on health research, and at Virgin Atlantic Limited.

Tim studied chemistry at Oxford University.

Chair of the Management Engagement & Remuneration Committee and a member of the Audit & Risk and Nominations Committees.

Joanne Joined the Board on 1 September 2022. A Chartered Accountant, Joanne is a non-executive Director and Chair of the Audit Committee of Henderson International Income Trust plc, and a non-executive Director of Octopus AIM VCT. She is also a non-executive Director and Chair of the Audit Committee of Start Codon Limited and IESO Digital Health Limited and the non-executive Chair of Babraham Research Campus Limited. Joanne was formerly a non-executive Director of Guy’s and St Thomas’ Enterprises Limited and of LGV Capital Partners Limited.

Joanne studied chemistry at Oxford University.